Integrating multi-omics and clinical management in breast cancer: a comprehensive review
Blood tests tracking circulating tumor DNA and cancer cells show promise for catching treatment resistance early in breast cancer, informing personalized care decisions.
This translational review uniquely integrates all molecular omics layers with tumor microenvironment profiling and clinical management guidance for breast cancer, positioning ctDNA, CTC, and exosome liquid biopsy as tools for minimal residual disease monitoring. The review outlines a translational roadmap addressing therapeutic resistance mechanisms with implications for personalized breast cancer management.
What the study was
- Study design
- Comprehensive narrative review
- Population
- Breast cancer patients (multi-omic and liquid biopsy data)
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Discover Oncology
Why it surfaced
Comprehensive multi-omics + liquid biopsy integration in breast cancer. Open-access review. Review design limits evidence score; China-based single institutional perspective.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.